Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Daily oral intake of 125 µg supplemental vitamin D3 led to a significant improvement in plasma 25(OH)D concentrations over the 8‐week intervention in the vitamin D group compared to the change in the placebo group (p ˂ 0.001).
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Mixed research settings
Reported blinded roles: participants.
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in the UK: A pilot randomised controlled trial
Source: Article title.
Participants were assigned to consume 125 µg day: 1 (5000 IU day: 1) vitamin D3 or placebo for 8 weeks.
Source: Abstract.
The trial was a randomised, double‐blinded and placebo‐controlled.
Source: Methods.
The investigator, participants and research staff were blinded to study allocation until the trial was completed.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in the UK: A pilot randomised controlled trial
Randomised controlled trial · Journal of Human Nutrition and Dietetics · 2022
Original publication title
Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in the UK: A pilot randomised controlled trial
© 2022 The Authors. Journal of Human Nutrition and Dietetics published by John Wiley & Sons Ltd on behalf of British Dietetic Association.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Observational studies suggest links between reduced serum 25(OH)D concentration and increased cardiometabolic disease risk. However, these studies provide limited evidence of causation, with few conclusive randomised controlled trials (RCT) having been carried out to date. This RCT investigated the effect of vitamin D3 supplementation on vascular function and cardiometabolic disease risk markers, in 55 healthy males aged 18 to 65 years with plasma 25(OH)D concentration <75 mol L: 1 and body mass index ≥24.9 kg m: 2.
Source: BackgroundAbstract: What methods does the paper describe?
Participants were assigned to consume 125 µg day: 1 (5000 IU day: 1) vitamin D3 or placebo for 8 weeks. Blood samples and vascular function measures were obtained at baseline, as well as at weeks 4 and 8. The primary outcome was arterial stiffness, an indicator of cardiovascular disease (CVD) risk, assessed by pulse wave velocity. Biomarkers of CVD risk, insulin resistance and endothelial function were measured using an enzyme‐linked immunosorbent assay.
Source: MethodsAbstract: Results
Daily oral intake of 125 µg supplemental vitamin D3 led to a significant improvement in plasma 25(OH)D concentrations over the 8‐week intervention in the vitamin D group compared to the change in the placebo group (p ˂ 0.001). In the vitamin D group, the baseline mean ± SD 25(OH)D concentration was 38.4 ± 15.9 and this increased to 72.8 ± 16.1 nmol L: 1 after 8 weeks of supplementation. The intervention had no effect on arterial stiffness, as measured by pulse wave velocity, although vitamin D3 supplementation did lead to a decrease in mean ± SD brachial pulse pressure from baseline to 8 weeks of −2.9 ± 3.4 mmHg (p = 0.027) in the vitamin D group compared to the same period in the placebo group.
The intervention had no effect on the remaining cardiometabolic parameters.
Source: ResultsAbstract: Conclusions
Overall, treatment significantly improved brachial pulse pressure but no other cardiometabolic disease risk markers. To follow on from this pilot RCT, future large‐scale clinical trials over longer durations may offer further insights.
Source: ConclusionsAuthors’ abstract
Abstract
Background
Observational studies suggest links between reduced serum 25(OH)D concentration and increased cardiometabolic disease risk. However, these studies provide limited evidence of causation, with few conclusive randomised controlled trials (RCT) having been carried out to date. This RCT investigated the effect of vitamin D3 supplementation on vascular function and cardiometabolic disease risk markers, in 55 healthy males aged 18 to 65 years with plasma 25(OH)D concentration <75 mol L: 1 and body mass index ≥24.9 kg m: 2.
Methods
Participants were assigned to consume 125 µg day: 1 (5000 IU day: 1) vitamin D3 or placebo for 8 weeks. Blood samples and vascular function measures were obtained at baseline, as well as at weeks 4 and 8. The primary outcome was arterial stiffness, an indicator of cardiovascular disease (CVD) risk, assessed by pulse wave velocity. Biomarkers of CVD risk, insulin resistance and endothelial function were measured using an enzyme‐linked immunosorbent assay.
Results
Daily oral intake of 125 µg supplemental vitamin D3 led to a significant improvement in plasma 25(OH)D concentrations over the 8‐week intervention in the vitamin D group compared to the change in the placebo group (p ˂ 0.001). In the vitamin D group, the baseline mean ± SD 25(OH)D concentration was 38.4 ± 15.9 and this increased to 72.8 ± 16.1 nmol L: 1 after 8 weeks of supplementation. The intervention had no effect on arterial stiffness, as measured by pulse wave velocity, although vitamin D3 supplementation did lead to a decrease in mean ± SD brachial pulse pressure from baseline to 8 weeks of −2.9 ± 3.4 mmHg (p = 0.027) in the vitamin D group compared to the same period in the placebo group.
The intervention had no effect on the remaining cardiometabolic parameters.
Conclusions
Overall, treatment significantly improved brachial pulse pressure but no other cardiometabolic disease risk markers. To follow on from this pilot RCT, future large‐scale clinical trials over longer durations may offer further insights.
Key points
This pilot randomised controlled trial investigated the effect of vitamin D3 on arterial stiffness, biomarkers of cardiovascular disease risk and insulin resistance in vitamin D insufficient overweight and obese adult males.
Supplementation significantly decreased brachial pulse pressure in the vitamin D3 group at 4 and 8 weeks but did not improve the other cardiometabolic markers measured.
The findings from the present study are in agreement with previous research that does not support the use of daily high‐dose vitamin D supplements for the purpose of reducing risk of cardiovascular disease.
Publication and source details
Original title: Effect of vitamin D3 supplementation on cardiometabolic disease risk among overweight/obese adult males in the UK: A pilot randomised controlled trial
Tarimoboere Agbalalah; Sohail Mushtaq
Journal of Human Nutrition and Dietetics · 2022
* Correspondence Tarimoboere Agbalalah, Department of Biological Sciences, Baze University, 2C44 + 7CR, Plot 686, Jabi Airport Road Bypass, Cadastral Zone, Abuja, Nigeria.Email: tarimoboere.agbalalah@bazeuniversity.edu.ng
© 2022 The Authors. Journal of Human Nutrition and Dietetics published by John Wiley & Sons Ltd on behalf of British Dietetic Association.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T09:24:06.715669+00:00
DOI: 10.1111/jhn.13021 · PMC10084017